Medicare Expands Coverage for Hologic’s Biotheranostics Breast Cancer Test

Hologic on Monday announced that its subsidiary, Biotheranostics, has received broader Medicare coverage (L37822) for its Breast Cancer Index test under an expanded Medicare local coverage determination.

The expanded coverage increases the availability of Breast Cancer Index testing with no cost to Medicare beneficiaries who meet the local coverage determination criteria, Hologic said. Citing National Cancer Institute data, the firm said that based on the expanded coverage, approximately 25,000 more women every year will be eligible for testing with Breast Cancer Index.

 

Source: https://www.genomeweb.com/reimbursement-news/medicare-expands-coverage-hologics-biotheranostics-breast-cancer-test